Sept 24 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS AND JAGUAR HEALTH ANNOUNCE STRATEGIC PARTNERSHIP
* KNIGHT THERAPEUTICS INC - TO BE RESPONSIBLE FOR ALL REGULATORY AND COMMERCIAL ACTIVITIES FOR MYTESI AND RELATED PRODUCTS IN LICENSED TERRITORIES
* KNIGHT THERAPEUTICS - UPON ACHIEVEMENT OF REGULATORY, SALES MILESTONES IN AGREEMENT, JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION
* KNIGHT THERAPEUTICS - AGREEMENT GRANTS CO EXCLUSIVE RIGHT TO COMMERCIALIZE MYTESI AND RELATED PRODUCTS IN CANADA AND ISRAEL
* KNIGHT THERAPEUTICS INC - AGREEMENT GRANTS CO A RIGHT OF FIRST NEGOTIATION TO COMMERCIALIZE MYTESI & RELATED PRODUCTS IN SPECIFIED LATAM COUNTRIES
* KNIGHT THERAPEUTICS INC - JAGUAR IS ALSO PURSUING POSSIBLE FOLLOW-ON INDICATIONS FOR MYTESI IN CANCER THERAPY-RELATED DIARRHEA
* KNIGHT THERAPEUTICS - JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION THROUGHOUT INITIAL 15-YEAR TERM OF AGREEMENT